British Infant Opal Regains Hearing After Groundbreaking Gene Therapy

Oxfordshire, England, England United Kingdom of Great Britain and Northern Ireland
British infant Opal underwent groundbreaking gene therapy for profound hearing loss
First successful gene therapy for infant with OTOF gene variant
Gene therapy delivered directly to cochlear results in fewer side effects
Impact on Opal's life significant as she was unable to respond to loud noises prior to treatment
Opal unable to hear any sounds before treatment, now able to hear soft sounds almost within normal range
British Infant Opal Regains Hearing After Groundbreaking Gene Therapy

In a groundbreaking development, a baby named Opal, who was born with profound hearing loss, has regained her ability to hear after undergoing gene therapy. This treatment marks the first time such a procedure has been successful for an infant. The trial for this innovative therapy targeted children with the OTOF gene variant that does not produce the necessary protein for hearing.

According to reports, Opal was unable to hear any sounds at all in her affected ear, even when they were very loud. However, following the treatment, she is now able to hear sounds at a soft level almost within the normal range for children her age. The therapy involves delivering a small dose of gene therapy directly to the cochlear, resulting in fewer side effects.

The success of this trial has been reported by various sources including The Cambridge Independent and The Washington Post. Opal is believed to be the first British patient and youngest child to undergo this type of treatment as part of a global trial. The gene therapy is being carried out at Addenbrooke's Hospital in Cambridge.

The impact of this breakthrough on Opal's life has been significant. Prior to the treatment, she was unable to respond to loud noises and would not turn towards them. However, following the therapy, she has shown remarkable progress and is now able to hear sounds that were previously inaudible.

This gene therapy offers hope for millions of people worldwide who suffer from hearing loss due to genetic causes. It represents a major step forward in the field of gene therapy and could potentially lead to new treatments for other genetic conditions.



Confidence

100%

No Doubts Found At Time Of Publication

Sources

100%

  • Unique Points
    • The baby, Opal, had profound hearing loss before gene therapy.
    • Opal cannot hear any sounds in that ear at all when they are very loud.
    • The trial was for children who have the OTOF gene variant that does not produce a particular protein needed for hearing.
    • A small dose of gene therapy is delivered directly to the cochlear, resulting in fewer side effects.
    • Opal can now hear sounds at a very soft level almost in the normal range for children her age.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

98%

  • Unique Points
    • An 18-month-old underwent a new form of gene therapy, making them the first person to do so.
    • The success of the gene therapy was reported by ABC News.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

  • Unique Points
    • Baby girl Opal Sandy from Oxfordshire, England received groundbreaking gene therapy for profound genetic deafness
    • Opal is the first British patient and youngest child to undergo this type of treatment in a global trial
    • Gene therapy trial at Addenbrooke’s Hospital in Cambridge showing mind-blowing results
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication